Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 331 to 345 of 529 results for drug monitoring

  1. Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2 (TA257)

    Evidence-based recommendations on lapatinib (Tyverb) and trastuzumab (Herceptin) for treating metastatic hormone receptor-positive breast cancer that overexpresses HER2 in adults.

  2. Anakinra for treating Still's disease (TA685)

    Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.

  3. Oesophago-gastric cancer: assessment and management in adults (NG83)

    This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.

  4. Chronic heart failure in adults (QS9)

    This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.

  5. Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome (MIB223)

    NICE has developed a medtech innovation briefing (MIB) on Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome .

  6. VA ECMO for severe acute heart failure in adults (HTG764)

    Evidence-based recommendations on venoarterial extracorporeal membrane oxygenation (VA ECMO) for severe acute heart failure in adults. This involves using an artificial lung to oxygenate the blood outside the body.

  7. Treatment of convulsive status epilepticus (that is, not just refractory): What is the most effective and safest AED to treat: established (usually lasting longer than 30 minutes) convulsive status epilepticus refractory convulsive status epilepticus?

    used medication is phenytoin. This should be used with care and close monitoring because of the risk of hypotension and cardiac...

  8. Permanent His-bundle pacemaker implantation for treating heart failure (HTG579)

    Evidence-based recommendations on permanent His-bundle pacemaker implantation for treating heart failure. This involves attaching a wire connected to a pacemaker to the heart’s electrical conduction pathway (through a vein).

  9. gammaCore for cluster headache (HTG533)

    Evidence-based recommendations on gammaCore for cluster headache.

  10. Sofosbuvir for treating chronic hepatitis C (TA330)

    Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)

  11. Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.

  12. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

  13. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.

  14. Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)

    Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults.

  15. Otovent nasal balloon for otitis media with effusion (MIB59)

    NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion